Toronto, Ontario–(Newsfile Corp. – October 8, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, CEO of Awakn Life Sciences, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021.
Anthony Tennyson will present live on Wednesday, October 13th at 10:30 a.m. ET. Register to attend here.
For more information about the conference, or to schedule a one-on-one meeting with Awakn’s management team, please contact KCSA Strategic Communications at Awakn@kcsa.com.
Awakn also announces it has retained the services of JRZ Capital LLC (“JRZ”), an investor communications and public relations company, to assist the Company to enhance its market awareness, and communications strategy. JRZ has agreed to comply with all applicable securities laws and the policies of all applicable stock exchanges in providing services to the Company. Under the terms of the JRZ engagement, which is for an initial two-month period, JRZ will be paid US$150,000 per month.
About Awakn Life Sciences Corp.
Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver these evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally.
www.awaknlifesciences.com | Twitter | LinkedIn | Facebook
Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com
Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com
Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99032
Study Marks Milestone in Precision Psychiatry for Stress-Axis-Related DepressionMUNICH, Jan. 10, 2025 (GLOBE NEWSWIRE) --…
- Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply…
This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered…
"Solo practitioners face unique challenges in managing their credentialing needs," says Olga Khabinskay, Director of…
In Q1 2025, the Company will discuss the plans for NDA submission under a potential…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical…